anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Sore and furuncle relates to acute suppurative inflammation caused by hair follicle or glandula sebacea. The furunculosis can be seen most frequently in faces and limb endings, and has a small shape like a nail and has a deep root. At first, the furunculosis mostly has a pus head at the top and a hard periphery, and is paint and itchy accompanied with chills and fever and dizziness. The furunculosis develops rapidly. If symptoms of suddenly blackened and sank sore heads, blurred mind, high fever, and the like occur, &#34;furunculosis proliferation&#34; (septicemia) is developed and is the most critical and should be treated as soon as possible. Carbuncle is developed by fusion of a plurality of furuncles and can be seen most frequently in neck and back parts. Only a pus head is existed at first with red and swollen periphery skin, then the red and swollen area expands and a plurality of the pus heads occur with severe pain, high fever, chill, headache, dizziness, and other symptoms. An effective prescription of decocting and taking honeysuckle and other compatible traditional Chinese medicines in a technical scheme is a secret recipe. Based on repeated research and clinical observation and cure and by repeated practice, a newest treating scheme is developed innovatively. A method of sterilization and toxin removal is a novel treating method for the malignant furunculosis. The effective prescription can rapidly kill viruses and bacteria and prevent malignant furunculosis root extension.
A problem to be solved is to provide an orally ingestible composition which promotes the production of adiponectin and which is free from safety issues such as side effects and toxicity. An adiponectin production promoting composition is prepared which comprises salmon milt extract, brewer&#39;s yeast extract, avian collagen, and yeast containing mineral and having an adiponectin production promoting activity. Preferably, the salmon milt extract comprises low molecular weight components obtained by enzymatic degradation of salmon milt into oligonucleotides and oligopeptides. Preferably, the brewer&#39;s yeast extract comprises 50 to 80% of RNA. Preferably, the yeast containing mineral comprises, in dry yeast, 2 to 3% of zinc, 0.3 to 0.5% of copper, and 0.01 to 0.02% of selenium. Preferably, the adiponectin production promoting composition comprises 16 to 17 parts by mass of the brewer&#39;s yeast extract, 33 to 34 parts by mass of the avian collagen, and 22 to 23 parts by mass of the yeast containing mineral per 100 parts by mass of the salmon milt extract.
PROBLEM TO BE SOLVED: To obtain the subject composition rapidly and nearly completely soluble even in a small amount of water at low temperatures by incorporating a foaming agent with acetaminophen having each specific range of bulk density and particle size. SOLUTION: This composition is obtained by formulating a foaming agent [pref. composed of a basic composition containing an agent acting as a carbon dioxide source (e.g. sodium bicarbonate) and an acidic composition containing an agent inducing carbon dioxide release (e.g. tartaric acid, citric acid, ascorbic acid)] with pref. 2-40 wt.%, more pref. 5-20 wt.% of acetaminophen with a bulk density of &lt;0.2 g/mL, pref. 0.12-0.18 g/mL, and particle size of 1-50 μm, pref. a median size of 3-20 μm, more pref. 5-10 μm.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antibacterial composition comprising a galloyl glucose as an active ingredient, to provide an antibacterial agent comprising the composition and to provide a method for extracting the galloyl glucose.  &lt;P&gt;SOLUTION: The antibacterial composition comprises the galloyl glucose (e.g. 1,2,3,4,6-pentagalloyl glucose, 1,2,3,6-tetragalloyl glucose, 1,2,4,6-tetragalloyl glucose and 2,3,4,6-tetragalloyl glucose) as the active ingredient. The method for extracting the galloyl glucose comprises a step of obtaining a solvent extract from Paoneia albiflora Pall. by solid-liquid extraction, a step of fractionating a component containing the antibacterial substance from the solvent extract by a chromtography and a step of separating at least the galloyl glucose from the component containing the antibacterial substance by the chromatography.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The present invention describes novel treatments for movement disorders, including tardive dyskinesia and tardive dystonia, tic disorders, Tourette&#39;s syndrome, and blepharospasm, and other focal dystonias. The treatments of the present invention utilize agents that simultaneously act as NMDA-type glutamate receptor antagonists. Additionally, the treatments of the present invention utilize agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that can be used in combination with a treatment for movement disorders, that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.
NEW MATERIAL:A compound expressed by formula I (-COOR represents carboxylate ion, carboxylic acid, etc.; X&lt;-&gt; represents anion constituting acid; provided that X is not necessarily required when -COOR is carboxylate ion) and salt thereof. EXAMPLE:7beta-Amino-3-[4-(oxazol-5-yl)-1-pyridinio]methyl-3-cephem-4-c arboxylate hydrochloride. USE:A synthetic intermediate for cephalosporin based antibiotic, isolable as crystals and capable of increasing the purity of the final medicament. PREPARATION:A starting compound expressed by formula II (R2 represents alkyl capable of being substituted by phenylmethyl, etc.; R3 represents H, Na, etc.; Y represents halogen atom; Z is Y) is quaternized by an excess 5-(4- pyridyl)oxazole in an organic solvent such as acetone. Then the obtained com pound expressed by formula III is treated with PCl5, etc., in the presence of a base and thus obtained solution of an imino chloride is mixed with a solvent solution of an alcohol to deacylate a compound expressed by formula III to obtain a compound expressed by formula I.
Disclosed is a suppressor of the expression of MCP-1, which is highly safe and can be applied widely to a food or the like. The suppressor comprises aurapten. Aurapten is contained in a citrus fruit such as &#39;Hassaku&#39; (Citrus hassaku Hort.ex TANAKA), &#39;Amanatsu&#39; (Citrus natsudaidai HAYATA), &#39;Natsumikan&#39; (Citrus natsudaidai HAYATA, a variant species) and Grapefruit (Citrus paradisi). Since these citrus fruits have been eaten for many years, the suppressor is free of a safety problem. Further, when added to a food or the like, aurapten does not impair the flavor of the food or the like because of its almost tasteless and odorless properties. Still further, aurapten can be ingested over a long period even in an obese person, a diabetic patient or the like because of its low-calorie property. Aurapten can suppress the expression of MCP-1 at a gene level (see Fig. 1) or a protein level.
PURPOSE:To obtain an emulsified compsn. having excellent emulsification stability by incorporating &gt;=1 or 2 kinds of phosphates of hydroxyalkyl or hydroxyalkenyl compds. expressed by the specific constitutional formulas. CONSTITUTION:The phosphate of hydroxyalkyl or hydroxyalkenyl compds. expressed by the formulaIand/or formula II (in the formula, R is the same or different and denotes an alkyl or alkenyl group respectively of 5-20 carbon atoms, X1, X2 denote the ion pair selected from the group consisting of hydrogen, alkali metals, ammonium, alkylammonium having alkyl groups of 1-5 carbon atoms, and alkanol amine having hydroxyalkyl groups of 2 or 3 carbon atoms) are compounded, whereby the emulsified compsn. is prepd.
Prepn. of an extract of unroasted coffee comprises: (i) treating ground coffee with a first solvent to dissolve the fats and caffeine; (ii) treating the ground prod. with a mixt. of polar solvent and water to dissolve chlorogenic acids; (iii) eliminating the polar solvent and treating the resulting aq. soln. with a third solvent which is immiscible with water to dissolve the chlorogenic acids; and (iv) evaporating the organic soln. to obtain a dry extract. The extract is claimed per se.  The first solvent is CHCl3 or CH2Cl2, the second solvent is MeOH /water pref. in a 7/2-7/4 vol. ratio and the third solvent is EtOAc. Elimination of the polar solvent and evapn. of immiscible solvent is under reduced press. at &lt; 50  deg C.
PURPOSE:To obtain a hair cosmetic having excellent conditioning property by using a specific modified solid silicone polymer, a cationic surfactant, an oil and fat, an organic liquid containing at least one hydroxyl group in one molecule and compatible with water, and water as essential components. CONSTITUTION:The objective hair cosmetic contains (A) a modified silicone polymer containing one or more alkoxy groups in the molecule and having a melting point of &gt;=30 deg.C [e.g. a compound of formula ((l) is 1-100; (m) is 1-50)], (B) a cationic surfactant (e.g. a quaternary ammonium salt), (C) an oil and fat (e.g. liquid paraffin and lanolin), (D) an organic liquid having one or more hydroxyl groups in one molecule and compatible with water (e.g. polyhydric alcohol) and (E) water. The hair treated with the hair cosmetic is free from oily feeling even in wet state or dried state, has excellent smoothness and flexibility, gives bulky and light texture and moist feeling and exhibits excellent antistatic effect. The cosmetic has excellent storage stability.
The present invention relates generally to a ciagrette substitute for administering a dose of nicotine. More specifically, the present invention is directed to a nicotine-containing dosage-form comprising a holder member which may be used as part of an effective smoking cessation program or in situations where smoking is undesirable or not permitted. The dosage form is configured as a dosage form having a nicotine-containing composition attached to a holder member. Nicotine is released from the dosage form and absorbed through the intra-oral mucosal surfaces as the nicotine-containing composition releases nicotine within a user&#39;s mouth. The holder member facilitates insertion and removal of the dosage form into and out of a user&#39;s mouth. The user can selectively insert and remove the dosage form as desired to selectively control the release of nicotine. In addition, the user can insert and remove the dosage form in a manner which meets the user&#39;s psychological need or desire for ritualistic oral stimulation similar to cigarette smoking.
An improved emergency response system is provided. The system includes a patient or subscriber location database having a schedule of patient or subscriber activities. In one implementation, an emergency services server detects when the patient or subscriber is having a possible medical event as indicated by medical physiologic data transmitted from a wireless communication device proximate the patient. A third party such as a technologist and/or doctor diagnoses the patient and determines whether treatment is required. If treatment is required, a phone located remotely from the patient is used to call an emergency services first responder from a public safety access point in the patient&#39;s location. The remotely located phone has an automatic location identification database record that is updated based on the patient&#39;s current location as indicate by the patient location database.  The address information in the patient location database includes street number, building number, floor and room number infomiation, if applicable, to ensure that first responders are directed to the patient&#39;s specific location. Other implementations of the emergency response system are also described, including natural disasters, home security, and travel applications.
PURPOSE:To obtain a skin protecting agent composition consisting of an acryl- based copolymer and medium, containing no organic solvent which irritates skin, having remarkably excellent irritating substance-shielding effect and forming a skin film capable of readily removing. CONSTITUTION:The objective composition obtained by containing 40 to 85wt.% alkyl acrylate, 5 to 50wt.% alkyl methacrylate and 10 to 30wt.% carboxyl group-containing monoethylene-based unsaturated monomer, and as necessary, adding other monomers consisting of vinyl acetate, N-vinylpyrrolidone, etc., to the above-mentioned three components at an amount of &lt;=20 pts.wt. based on 100 pts.wt. total amount of the three components and polymerizing the above- mentioned monomers according to ordinary method to provide an acryl-based copolymer and adding a medium (e.g. ethanol) to the resultant copolymer. The objective composition can be prepared in the form of a solution, cream, spray liquid, etc.
The invention provides a traditional Chinese medicine composition for treating endometriosis, which takes salvia miltiorrhiza and dragon&#39;s blood as monarch drugs, removes stasis, promotes tissue regeneration, and is regulated to be later used for treating endometriosis. The zedoary, the cattail pollen charcoal, the sargentgloryvine stem, the prepared nutgrass galingale rhizome and the fried fennel are compatible, the qi and the blood are treated simultaneously, the qi circulation is followed by the blood circulation, and the blood circulation is followed by the pain relief, and the zedoary, the cattail pollen charcoal, the sargentgloryvine stem, the prepared nutgrass galingale. Radix astragali Preparata, rhizoma Dioscoreae, Coicis semen, Prunellae Spica, and radix scrophulariae are used as adjuvant drugs for removing blood stasis and promoting regeneration without impairment of healthy qi. Prepared licorice root, radix Glycyrrhizae Praeparata coordinates the effects of the other drugs in the recipe. The whole formula has the effects of activating blood and stimulating the menstrual flow, and eliminating abdominal mass and relieving pain. Has definite curative effect on endometriosis and is not easy to relapse after healing.
Embodiments herein include medical systems, devices, and methods for assessing the health status of a patient. In an embodiment, a method includes evaluating the presence of volatile organic compounds in a breath or gas sample of the patient with a plurality of graphene sensors to generate volatile organic compound data, wherein the plurality of graphene sensors include sensors that are specific for different volatile organic compounds. The method can further include collecting data regarding the patient&#39;s sympathetic nervous activity. The method can further include combining the volatile organic compound data with the collected data regarding the patient&#39;s sympathetic nervous activity to form a combined data set. The method can further include matching the combined data set against one or more data patterns to find the best match, the best match indicating the health status of the patient. Other embodiments are also included herein.
The invention encompasses a method of down-regulating a T cell-mediated immune response, through activation or T cell receptor (TCR) stimulation of antigen-primed T cells in the presence of alpha-melanocyte stimulating hormone (.alpha.-MSH), which may be optionally enhanced by adding transforming growth factor-.beta.2 (TGF-.beta.2) approximately 4-6 hours after the start of the primed T cells&#39; exposure to .alpha.-MSH. Activation of the primed T cells may be mediated by presentation of the specific antigen to the primed T cells, or by an anti-TCR antibody or a T cell mitogen. As a result of the .alpha.-MSH  treatment modulating the T cell activation, antigen-specific, regulatory, CD4+/CD25+ T cells are generated that produce transforming growth factor-.beta. (TGF-.beta.) and can non-specifically down-regulate Th1-mediated inflammatory activities. The method may be used to down-regulate or suppress an autoimmune condition or a graft rejection in a transplant patient. The invention also encompasses a kit for generating regulatory T cell comprising a speciric antigen, .alpha.-MSH, and optionally, TGF-.beta.2 and/or a T cell culture medium. Also provided are gene therapy treatments for suppressing an autoimmune or graft rejection response, or for re-establishing autotolerance, by introducing genetic material (e.g. nucleic acid) for expressing .alpha.-MSH  or a receptor-binding portion thereof, into a localized tissue site.
FIELD: medicine, phytotherapy, sexology. SUBSTANCE: invention relates to the development of species prepared of the plant raw for increase of male potency. The species &#34;Gusarsky&#34; has 23 plants taken at the definite ratio and after oral intake it shows good clinical results. The species elicits tonic and sedative effect and recovers sexual potency. EFFECT: enhanced effectiveness of the species. 1 cl
The proposed study responds to the need for community-engaged interventions to increase vaccine uptake among populations experiencing health disparities. We focus on COVID-19 and influenza vaccination, both of which now require annual vaccines. Among those at highest risk for morbidity, hospitalization, and mortality are African American/Black and Latino (ABBL) persons who are not up-to-date on these vaccinations. Only 20-28% of adult AABL persons are up-to-date on COVID-19 vaccination, compared to 31% of White persons, and only 30-40% of AABL persons receive the influenza vaccine annually compared to \&amp;gt;55% among White persons. AABL experience serious impediments to COVID-19 (and to a lesser extent, influenza) vaccination at individual- (e.g., distrust, insufficient knowledge, low perceived risk, cognitive biases), social- (e.g., peer norms), and structural-levels of influence (e.g., poor access). Taken together, these comprise multi-level vaccine hesitancy. Factors that promote vaccination include trusted AABL health educators (peers, nurses), tapping into altruism and collective responsibility, circumventing cognitive biases, and reducing structural barriers. Without efforts to address multi-level vaccine hesitancy, rates of COVID-19 and influenza vaccination will remain unacceptably low and racial/ethnic health disparities in infectious disease morbidity and mortality will persist. The proposed study is led by a collaborative team at New York University and the Northern Manhattan Improvement Corporation. It uses the multiphase optimization strategy (MOST), an engineering-inspired framework, to test effects of individual candidate intervention components in a factorial design and then optimize a multi-component intervention made up of the most cost-effective combination of components. Staying up-to-date with COVID-19 vaccination (confirmed with documentary evidence) is the primary outcome, and influenza vaccination is the secondary outcome. We have identified four promising candidate components, with an emphasis on brevity, low-touch, and future scalability: A) nurse-led shared decision making, B) a text message intervention, C) modest lottery prizes for vaccination, and D) peer navigation to vaccination appointments. Participants will be N=560 community-residing adult English and Spanish-speaking AABL persons who are not up-to-date on COVID-19 and influenza vaccinations but with at least one COVID-19 vaccine dose. Specific aims are: Aim 1) identify which of four components contribute meaningfully to improvement in the outcomes; Aim 2) identify mediators (e.g., altruism, norms) and moderators (e.g., sociodemographic characteristics, distrust) of the effects of each component; and Aim 3) build the most cost-effective intervention package(s). Participants will be randomly assigned to an experimental condition, and assessed at 3- and 6-months post-baseline; N=45 participants will engage in qualitative in-depth interviews. We will also uncover, describe, and plan for implementation issues so the optimized intervention can be rapidly scaled up by community-based and outpatient health organizations.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a hesperetin-7-β-maltoside and to provide uses thereof.  &lt;P&gt;SOLUTION: The method for producing the hesperetin-7-β-maltoside is characterized as follows. Hesperidin is reacted with an enzyme having an α-1,6-rhamnosidase activity to remove rhamnose. The resultant 7-β-D-monoglucosyl hesperetin is reacted with a glycosyltransferase in the presence of starch or dextrin to add one or more α-D-glucoses. A method for producing a hesperetin glycoside composition containing the hesperetin-7-β-maltoside is characterized as follows. The resultant addition product is reacted with a hydrolase to reduce the average number of added glucoses. Thereby, the average number of added glucoses is regulated to 1.5-3.0 based on the 7-β-D-monoglucosyl hesperetin. A method for improving the water solubility of a sparingly water-soluble substance comprises making the sparingly water-soluble substance selected from the hesperidin, the 7-β-D-monoglucosyl hesperetin, hesperetin, rutin, naringin and isoflavone coexist with the hesperetin-7-β-maltoside.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
FIELD: medicine, biochemistry. SUBSTANCE: invention is related to the long-term modification and regulation of lipid and carbohydrate metabolism, obesity decrease, decrease of resistance to insulin, hyperinsulinemia and hyperglycaemia or both (typical traits of insulin-nondepending diabetes, diabetes of type II). Method involves the administration of bromocriptine (dopamine against) to human or animals by oral, sublingual or parenteral routes. Bromocriptine is administrated at the definite limited time of day depending on the normal circadian rhythm in insulin-resistant and insulin-sensitive representatives of related species. Resistance to insulin, hyperinsulinemia and hyperglycaemia or both can be controlled in human on the long-term basis of proposed treatment since short-term diurnal preparation administration corrects the hormonal &#34;schedule&#34; in brain nervous centers that makes the long-term effect. EFFECT: improved method of treatment.
The present invention relates to an anti-senility health care medicine. The formula of the present invention comprises cocoons and silk. The main components of the present invention are amino acids, and especially lysine and serine. The raw materials of the formula are dried and pulverized into powder to be prepared into powdered preparations and capsules. The present invention has the advantages of abundant medicine sources, no toxic or side effect, specific curative effect and unique components in the present invention. The anti-senility health care medicine can be prepared into powdered preparations and capsules without a heating process, the chemical components can not be damaged, and the medicinal effect can reach 100%; the expectation effect before diseases are treated can be achieved, and the present invention is convenient to carry and take. The present invention can remove all &#39;refuse&#39; in human bodies, and has specific curative effects on resisting senility, treating three kinds of exhaustion syndrome, eliminating snore and treating insomnia.